Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy

Burles A. Johnson, Babak Baban, Andrew L'Mellor

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)645-661
Number of pages17
JournalImmunotherapy
Volume1
Issue number4
DOIs
StatePublished - Jul 1 2009

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Immunotherapy
Tissue Survival
Immune Tolerance
Dendritic Cells
Bystander Effect
T-Lymphocytes
Regulatory T-Lymphocytes
Autoimmune Diseases
Chronic Disease
Inflammation
Antigens
Enzymes
Infection
Neoplasms

Keywords

  • Allergy
  • Autoimmunity
  • Cancer
  • Dendritic cell
  • Immunoregulation
  • Indoleamine 2,3 dioxygenase
  • Infection
  • Inflammation
  • T cell
  • Tryptophan

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. / Johnson, Burles A.; Baban, Babak; L'Mellor, Andrew.

In: Immunotherapy, Vol. 1, No. 4, 01.07.2009, p. 645-661.

Research output: Contribution to journalReview article

Johnson, Burles A. ; Baban, Babak ; L'Mellor, Andrew. / Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. In: Immunotherapy. 2009 ; Vol. 1, No. 4. pp. 645-661.
@article{c732a072cdcb4f078ca9eb5ef9e641f3,
title = "Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy",
abstract = "Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.",
keywords = "Allergy, Autoimmunity, Cancer, Dendritic cell, Immunoregulation, Indoleamine 2,3 dioxygenase, Infection, Inflammation, T cell, Tryptophan",
author = "Johnson, {Burles A.} and Babak Baban and Andrew L'Mellor",
year = "2009",
month = "7",
day = "1",
doi = "10.2217/IMT.09.21",
language = "English (US)",
volume = "1",
pages = "645--661",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy

AU - Johnson, Burles A.

AU - Baban, Babak

AU - L'Mellor, Andrew

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.

AB - Natural immune tolerance is a formidable barrier to successful immunotherapy to treat established cancers and chronic infections. Conversely, creating robust immune tolerance via immunotherapy is the major goal in treating autoimmune and allergic diseases, and enhancing survival of transplanted organs and tissues. In this review, we focus on a natural mechanism that creates local T-cell tolerance in many clinically relevant settings of chronic inflammation involving expression of the cytosolic enzyme indoleamine 2,3-dioxygenase (IDO) by specialized subsets of dendritic cells. IDO-expressing dendritic cells suppress antigen-specific T-cell responses directly, and induce bystander suppression by activating regulatory T cells. Thus, manipulating IDO is a promising strategy to treat a range of chronic inflammatory diseases.

KW - Allergy

KW - Autoimmunity

KW - Cancer

KW - Dendritic cell

KW - Immunoregulation

KW - Indoleamine 2,3 dioxygenase

KW - Infection

KW - Inflammation

KW - T cell

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=77953421676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953421676&partnerID=8YFLogxK

U2 - 10.2217/IMT.09.21

DO - 10.2217/IMT.09.21

M3 - Review article

C2 - 20161103

AN - SCOPUS:77953421676

VL - 1

SP - 645

EP - 661

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 4

ER -